Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CDAK

Codiak BioSciences (CDAK) Stock Price, News & Analysis

Codiak BioSciences logo

About Codiak BioSciences Stock (NASDAQ:CDAK)

Advanced Chart

Key Stats

Today's Range
$0.0016
$0.0016
50-Day Range
N/A
52-Week Range
$0.05
$6.98
Volume
N/A
Average Volume
1.37 million shs
Market Capitalization
$58,928.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive CDAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CDAK Stock News Headlines

Marvel Biosciences Corp MRVL
The most explosive assets in 2025?
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
CDAK.O
Codiak BioSciences Files For Chapter 11 Bankruptcy
See More Headlines

CDAK Stock Analysis - Frequently Asked Questions

Codiak BioSciences, Inc. (NASDAQ:CDAK) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.12. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $2.87 million. Codiak BioSciences had a negative trailing twelve-month return on equity of 109.51% and a negative net margin of 51.13%.

Codiak BioSciences (CDAK) raised $82 million in an initial public offering on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codiak BioSciences investors own include NIO (NIO), Advanced Micro Devices (AMD), Alibaba Group (BABA), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/04/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CDAK
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.16 million
Pretax Margin
-51.13%

Debt

Sales & Book Value

Annual Sales
$33.57 million
Price / Cash Flow
N/A
Book Value
$2.39 per share
Price / Book
0.00

Miscellaneous

Free Float
33,810,000
Market Cap
$58,928.00
Optionable
Not Optionable
Beta
3.71
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CDAK) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners